NCT02771197View on ClinicalTrials.gov

Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 28, 2016

Primary Completion Date

August 3, 2022

Study Completion Date

July 31, 2023

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Fludarabine

DRUG

Melphalan

DRUG

Pembrolizumab

Trial Locations (2)

30342

Blood and Marrow Transplant Group of Georgia, Atlanta

Northside Hospital, Atlanta

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Northside Hospital, Inc.

OTHER

NCT02771197 - Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant | Biotech Hunter | Biotech Hunter